Compare AstraZeneca plc (AZN) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs MGM Resorts International — how do they compare? AstraZeneca plc trades at $166.76 (market cap $253.13B), while MGM Resorts International trades at $46.89 (market cap $11.94B). The key difference: AstraZeneca plc is far larger — about 21.2× MGM Resorts International's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | MGM | |
|---|---|---|
Market Cap | $253.13B | $11.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $50.69 |
52-Week Low | $137.44 | $30.72 |
Enterprise Value | $279.37B | $40.98B |
Dividend Yield | 1.92% | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
MGM Resorts International (MGM) trades at $47.24, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $48.93. Recent financials show revenue growth to $17.54B in 2025, though net income margin remains thin at 1.03%. The stock is buoyed by acquisition talks with Barry Diller's People Inc. at $48.30 per share, as reported by The Wall Street Journal on July 10, 2026, and positive cash flow projections for 2026.
Outlook: MGM offers moderate upside potential driven by acquisition interest and steady revenue, but risks include volatile earnings, high debt, and regulatory scrutiny. Investors should weigh the takeover premium against fundamental weakness in profitability and execution risks in the competitive casino sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
